JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257385

Human CD70 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

CD70 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
1 Images
Sanger Sequencing - Human CD70 knockout HeLa cell lysate (AB257385)
  • Sanger seq

Unknown

Sanger Sequencing - Human CD70 knockout HeLa cell lysate (AB257385)

Homozygous : 1 bp deletion in exon 1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257385-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human CD70 knockout HeLa cell lysate", "number":"AB257385-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257385-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
CD70
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD70 also known as CD27 ligand or CD27L is a type II transmembrane protein with a molecular mass of approximately 30 kDa. It belongs to the tumor necrosis factor (TNF) superfamily and is encoded by the CD70 gene. The expression of CD70 occurs mainly on activated T and B cells dendritic cells and some NK cells but not on resting lymphocytes. In addition CD70 expression is observed in certain malignancies and inflammatory conditions.
Biological function summary

CD70 plays an essential role in the regulation of immune responses. It does this by binding to its receptor CD27 forming a receptor-ligand complex that triggers signaling pathways vital for T cell proliferation survival and differentiation. This interaction also influences the production of immunoglobulins by B cells. CD70-CD27 signaling is particularly important in shaping adaptive immunity enhancing the body's ability to respond to pathogens effectively.

Pathways

CD70 is integral in the activation of the NF-κB and MAPK pathways. These pathways are activated upon the interaction of CD70 with CD27 promoting cell survival proliferation and pro-inflammatory cytokine production. Other proteins related to CD70 through these pathways include TRAF2 and TRAF3 which are essential for downstream signaling events that modulate immune responses.

CD70 has been implicated in autoimmune diseases and certain cancers. For instance it plays a role in the pathogenesis of lupus by contributing to abnormal immune activation. Overexpression of CD70 is also associated with various cancers such as renal cell carcinoma where it can support tumor cell growth and immune evasion. Through these conditions CD70 interacts with proteins like BCL-2 in cancer affecting cell survival pathways while its interaction with CD27 influences the immune deregulation seen in lupus.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com